BioNTech is a German biotechnology company known for its pioneering work in the development of mRNA-based therapeutics and vaccines. Founded in 2008, the company gained international recognition for its role in creating one of the first effective COVID-19 vaccines in collaboration with Pfizer. BioNTech focuses on the discovery and development of individualized cancer immunotherapies and vaccines, leveraging its expertise in messenger RNA (mRNA) technology to design treatments that prompt the immune system to combat diseases. The company aims to revolutionize medicine by utilizing its innovative approach to target various diseases, especially cancer and infectious diseases.
BioNTech's 2024 Q4 earnings per share (EPS) reached €1.08, surpassing forecasts but down from €1.90 the previous year. Revenue decreased from €1.479 billion to €1.19 billion, though exceeded expectations of…